Summit Therapeutics expands ivonescimab development with SMT112-216 trial
Summit Therapeutics opens a global Phase 2 kidney cancer trial testing ivonescimab combinations against established immunotherapy. What comes next?
Pharma & Biotech
Pharma & Biotech
Cadonilimab delivered 84.6% complete responses in an earlier study. Can Akeso prove lasting benefit?
Akeso starts Phase III cadonilimab testing in colon cancer, with 386 patients planned and recurrence outcomes central to its clinical strategy.
Pharma & Biotech
Akeso adds B7-H3 to its ADC strategy, but AK157D1 enters a field where a rival is already under FDA review
China has cleared Akeso’s AK157D1 for Phase 1 testing in advanced solid tumors, adding a DXd-class B7-H3 programme to a target already attracting late-stage ADC competition.
Pharma & Biotech
What the Akeso–INOVIO immunotherapy collaboration signals for the future of glioblastoma clinical research
Akeso and INOVIO test cadonilimab plus INO-5412 in the INSIGhT glioblastoma trial. Explore what this immunotherapy strategy could mean for GBM research.
Pharma & Biotech
Akeso’s cadonilimab outperforms PD-1 inhibitors in real-world gastric cancer study
Cadonilimab outperforms PD-1 inhibitors in PD-L1-low gastric cancer patients. Find out what this means for global immunotherapy standards.
Pharma & Biotech
Can Akeso’s cadonilimab unlock PD-L1-agnostic immunotherapy for gastric cancer patients?
Akeso Inc. has secured clearance from the United States Food and Drug Administration to initiate COMPASSION-37, a global Phase III trial evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, as part of a first-line treatment regimen for HER2-negative, unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. The randomized, multicenter trial will compare cadonilimab plus chemotherapy against